An Open-label, Single Arm Phase II Study of DFV890 to Assess the Safety, Tolerability and Efficacy in Participants With Familial Cold Auto-inflammatory Syndrome (FCAS)
Latest Information Update: 08 May 2024
At a glance
- Drugs DFV 890 (Primary)
- Indications Cryopyrin-associated periodic syndromes
- Focus Therapeutic Use
- Acronyms DFV890-FCAS
- Sponsors Novartis Pharmaceuticals
- 18 May 2023 Status changed from recruiting to completed.
- 12 Apr 2023 Planned End Date changed from 19 Mar 2023 to 2 Jun 2023.
- 12 Apr 2023 Planned primary completion date changed from 3 Mar 2023 to 15 May 2023.